Misconduct in the biomedical sciences part 2: detection and prevention By Dr Gerald H. Lushington and Rathnam Chaguturu Discovering safe and effective medicines, one of the greatest gifts to humanity, relies intensely upon the availability of detailed, unassailably accurate biomedical scientific knowledge. The key distinction that separates science from other… Read More
Anti-Infective Immunotherapy For Treating Hospital Acquired Infections By Dr Vu Truong, Dr Nadine Weich, Dr Andreas Loos and Dr Eric Patzer The frequency of nosocomial (acquired in healthcare facility) pneumonia has experienced a steady increase in recent years, and treatment of these infections has become more challenging and expensive due… Read More
Adoptive T-Cell Therapies: unlocking the potential of engineered antigen receptors By Dr Cenk Sumen, Dr Dan Williams and Dr Gwendolyn Binder-Scholl T-cells with engineered receptors to target tumours represent living drugs with enormous potential in the fight against cancer, but many challenges remain to be overcome in order for their… Read More
Experimental therapeutics for celiac disease and refractory celiac disease. By Dr Francisco Leon and Beth Llewellyn Celiac disease is a permanent immunological intolerance to gluten proteins in genetically predisposed individuals. In celiac patients, gluten causes a systemic autoimmune disease which starts in the small intestine but spreads to other organs… Read More
Precise genome editing: the key to a CRISPR drug discovery pipeline? By Dr. J. D. Wrigley, Dr M Maresca, Dr K Birmingham, Dr M Bohlooly-Y and Dr L M. Mayr From the pioneering days of Watson and Crick in 1953, to completion of the human genome project in 2003, advances… Read More
Misconduct in the biomedical sciences part 1: issues and causes By Dr Gerald H. Lushington and Rathnam Chaguturu Science pursues truth. Real advances in biomedical sciences improve our quality of life and save lives, but the path to these advances is cluttered with the distraction of irreproducible results - an… Read More
Therapeutic Drug Repurposing, Repositioning and Rescue Part II: Business Review By Dr Stephen Naylor, David M. Kauppi and Judge M. Schonfeld There is an emerging consensus that the impact of Drug Repurposing, Repositioning and Rescue (DRPx) on the pharmaceutical industry is real and sustainable. The activity and productivity of DRPx… Read More
Immunotherapy: The coming of age of cancer immunotherapy as a treatment paradigm By Dr Jean Pierre Wery As the oncology drug development landscape has evolved, so too have the processes, methods and equipment used in the fight against cancer. Traditional treatments such as chemotherapy and radiation therapy are still very… Read More
Restucturing Proteomics: The rise of next-generation affinity reagents By Dr Paul Ko Ferrigno & Dr Jane McLeod The ability of antibodies to bind their target proteins with some degree of specificity has elevated them to being among the most useful tools in biology and medicine, with a market value of… Read More
Immunoassay Automation: Hands-free platforms set to change the workflow in research labs By Dr John Comley The automation of immunoassays is not a new trend, but one that has already witnessed decades of innovation in diagnostic laboratories. However, in terms of hands-free automated processing of small batches of immunoassays in… Read More
Therapeutic Drug Repurposing, Repositioning and Rescue Part I: Overview By Dr Stephen Naylor & Judge M. Schonfeld The pharmaceutical industry is still beleaguered by escalating costs, stagnant productivity and protracted timelines as it struggles to bring therapeutic drugs to market. This situation has been compounded by a ravenous generic drug… Read More
Opportunities For Phenotypic Screening In Drug Discovery By David C. Swinney Renewed awareness of the value of phenotypic screening to drug discovery creates many new opportunities to increase drug discovery success and productivity. These opportunities include identification of translational phenotypic biomarkers, development of new assays that translate to human disease… Read More
Automated Patch Clamping Finally Achieves High Throughput By Dr John Comley Two new third-generation automated patch clamp (APC) systems capable of high throughput processing (10,000 data points per eight-hour day) and full robotic integration have been recently launched. The resulting wider choice of primarily 384 APC systems has the potential… Read More
There is no excerpt because this is a protected post. To read this content in full, you need to login. Not yet a DDW member? Join now for FREE – it takes less than 2 minutes! Username or E-mail Password Remember Me … Read More
Reconfiguring Drug Discovery Through Innovative Partnerships By Dr Robert Grundy, Iain James, Chas Bountra and Timothy Harrison Attrition rates in drug discovery and development remain stubbornly high, despite large investments by the pharmaceutical industry. The cost of developing a new drug has been estimated at between $1.3 billion and upwards… Read More
By Dr Scott R. Burger, Louis Juliano, and Dr Wenshi Wang For more than two decades, the biotechnology and pharmaceutical industries have been working to unlock the great potential of cell therapy, which uses products composed of living, functional cells to mediate the therapeutic effect. These novel biologics have potential… Read More